STAT+: Medicare starts process that could limit access to Biogen’s new Alzheimer’s drug

WASHINGTON — Federal officials on Monday announced Medicare will start a process that could limit seniors’ access to the controversial new Alzheimer’s drug, Aduhelm — the first signals from the key health program about what will be an enormously consequential decision for Biogen, the Medicare program itself, and people with the disease.

The process, called a National Coverage Determination analysis, ensures that coverage for the drug is uniform across the country instead of leaving decisions to regional contractors. The tool is rarely used for drugs, and Medicare announced its decision to use it much more quickly than is typical. If Medicare were going to pay for any Alzheimer’s patient’s treatment with Aduhelm, it likely would not need to use the tool.

Continue to STAT+ to read the full story…

STAT+: Medicare starts process that could limit access to Biogen’s new Alzheimer’s drug

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top